Opinion statement
Although autoimmune pancreatitis is a relatively uncommon pancreatic disorder, it is an important consideration in the differential diagnosis of jaundice and pancreatic masses to avoid unnecessary surgical resection. The clinical diagnosis of autoimmune pancreatitis involves considering multiple pieces of information including the pancreatic imaging, serum IgG4 level, presence of characteristic other involvement, and histologic findings. Unlike other pancreatic disorders, this condition rapidly responds to treatment with steroids. In the more common disease subtype (type 1 autoimmune pancreatitis) disease relapses can occur necessitating the use of maintenance treatment with low-dose steroids, steroid-sparing immunomodulators, or rituximab. This chapter reviews the diagnosis and treatment of the autoimmune pancreatitis subtypes.
Similar content being viewed by others
Abbreviations
- AIP:
-
Autoimmune pancreatitis
- GEL:
-
Granulocytic epithelial lesion
- ICDC:
-
International Consensus Diagnostic Criteria
- IDCP:
-
Idiopathic ductcentric chronic pancreatitis
- IgG4-RD:
-
IgG4-related disease
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Longnecker D. Evolution of the concept of autoimmune pancreatitis and its subtypes Pancreapedia: Exocrine Pancreas Knowledge Base. 2013.
Kawaguchi K, Koike M, Tsuruta K, Okamoto A, Tabata I, Fujita N. Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas. Hum Pathol. 1991;22(4):387–95.
Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40(7):1561–8.
Chari ST, Singer MV. The problem of classification and staging of chronic pancreatitis. Proposals based on current knowledge of its natural history. Scand J Gastroenterol. 1994;29(10):949–60.
Notohara K, Burgart LJ, Yadav D, Chari S, Smyrk TC. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol. 2003;27(8):1119–27.
Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 2010;139(1):140–148; quiz e12-3. https://doi.org/10.1053/j.gastro.2010.03.054.
Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62(12):1771–6. https://doi.org/10.1136/gutjnl-2012-303617.
Hart PA, Zen Y, Chari ST. Recent advances in autoimmune pancreatitis. Gastroenterology. 2015;149(1):39–51. https://doi.org/10.1053/j.gastro.2015.03.010.
Chari ST, Kloeppel G, Zhang L, Notohara K, Lerch MM, Shimosegawa T. Histopathologic and clinical subtypes of autoimmune pancreatitis: the Honolulu consensus document. Pancreas. 2010;39(5):549–54. https://doi.org/10.1097/MPA.0b013e3181e4d9e5.
Kamisawa T, Chari ST, Giday SA, Kim MH, Chung JB, Lee KT, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas. 2011;40(6):809–14. https://doi.org/10.1097/MPA.0b013e3182258a15.
Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58(11):1504–7. https://doi.org/10.1136/gut.2008.172908.
Detlefsen S, Zamboni G, Frulloni L, Feyerabend B, Braun F, Gerke O, et al. Clinical features and relapse rates after surgery in type 1 autoimmune pancreatitis differ from type 2: a study of 114 surgically treated European patients. Pancreatology. 2012;12(3):276–83. https://doi.org/10.1016/j.pan.2012.03.055.
Ryu JK, Chung JB, Park SW, Lee JK, Lee KT, Lee WJ, et al. Review of 67 patients with autoimmune pancreatitis in Korea: a multicenter nationwide study. Pancreas. 2008;37(4):377–85. https://doi.org/10.1097/MPA.0b013e31817a0914.
Sandanayake NS, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009;7(10):1089–96. https://doi.org/10.1016/j.cgh.2009.03.021.
Zamboni G, Luttges J, Capelli P, Frulloni L, Cavallini G, Pederzoli P, et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch. 2004;445(6):552–63. https://doi.org/10.1007/s00428-004-1140-z.
Huggett MT, Culver EL, Kumar M, Hurst JM, Rodriguez-Justo M, Chapman MH, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014;109(10):1675–83. https://doi.org/10.1038/ajg.2014.223.
Hart PA, Smyrk TC, Chari ST. Lymphoplasmacytic sclerosing pancreatitis without IgG4 tissue infiltration or serum IgG4 elevation: IgG4-related disease without IgG4. Mod Pathol. 2015;28(2):238–47. https://doi.org/10.1038/modpathol.2014.91.
Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352–8. https://doi.org/10.1097/MPA.0b013e3182142fd2.
Hart PA, Chari S. Diagnosis of Autoimmune Pancreatitis. Pancreapedia: Exocrine Pancreas Knowledge Base. 2013.
Hart PA, Levy MJ, Smyrk TC, Takahashi N, Abu Dayyeh BK, Clain JE, et al. Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience. Gut. 2016;65(10):1702–9. https://doi.org/10.1136/gutjnl-2015-309275.
•• Okazaki K, Chari ST, Frulloni L, Lerch MM, Kamisawa T, Kawa S, et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology. 2017;17(1):1–6. https://doi.org/10.1016/j.pan.2016.12.003. Consensus recommendations from the International Association of Pancreatology regarding the management of autoimmune pancreatitis.
Buijs J, van Heerde MJ, Rauws EA, de Buy Wenniger LJ, Hansen BE, Biermann K, et al. Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. Pancreas. 2014;43(2):261–7. https://doi.org/10.1097/MPA.0000000000000044.
Moon SH, Kim MH, Park DH, Hwang CY, Park SJ, Lee SS, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut. 2008;57(12):1704–12. https://doi.org/10.1136/gut.2008.150979.
Kamisawa T, Okazaki K, Kawa S, Ito T, Inui K, Irie H, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014;49(6):961–70. https://doi.org/10.1007/s00535-014-0945-z.
• Masamune A, Nishimori I, Kikuta K, Tsuji I, Mizuno N, Iiyama T, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut. 2017;66(3):487–94. https://doi.org/10.1136/gutjnl-2016-312049. Randomized clinical trial comparing the use of maintenance steroids versus no maintenance treatment for maintenance of disease remission.
Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62(11):1607–15. https://doi.org/10.1136/gutjnl-2012-302886.
• Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171–7. https://doi.org/10.1136/annrheumdis-2014-206605. Open label trial evaluating the efficacy of rituximab for treatment of IgG4-related disease.
Hart PA, Chari ST. Preventing disease relapses in autoimmune pancreatitis with maintenance steroids: are we there yet? Gut. 2017;66(3):394–6.https://doi.org/10.1136/gutjnl-2016-312738.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Phil A. Hart declares that he has no conflicts of interest. Somashekar G. Krishna declares that he has no conflicts of interest. Kazuichi Okazaki declares that he has no conflicts of interest.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Pancreas
Rights and permissions
About this article
Cite this article
Hart, P.A., Krishna, S.G. & Okazaki, K. Diagnosis and Management of Autoimmune Pancreatitis. Curr Treat Options Gastro 15, 538–547 (2017). https://doi.org/10.1007/s11938-017-0147-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11938-017-0147-x